Summary of medicine characteristics - LASYNAC 200 MG / 30 MG FILM-COATED TABLETS
Lasynac 200mg/30mg film coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each white film-coated tablet contains 200 mg ibuprofen and 30 mg pseudoephedrine hydrochloride.
Excipient(s) with known effect
Each tablet contains 84 mg of lactose monohydrate (see Section 4.4.).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film coated tablet.
White, round film coated tablets of 11mm in diameter.
4.1 Therapeutic indications
Symptomatic relief of nasal/sinus congestion with headache, fever, and pain associated with the common cold.
Lasynac is indicated in adults and adolescents aged 15 and above.
4.2 Posology and method of administration
Posology
Adults and adolescents aged 15 and above:
1 film-coated tablet (equivalent to 200 mg ibuprofen and 30 mg pseudoephedrine hydrochloride) every 6 hours if necessary.
For more severe symptoms, 2 film-coated tablets (equivalent to 400 mg ibuprofen and 60 mg pseudoephedrine hydrochloride) every 6 hours if necessary, to a maximum total daily dose of 6 film-coated tablets (equivalent to 1200 mg ibuprofen and 180 mg pseudoephedrine hydrochloride).
The maximum total daily dose of 6 film-coated tablets (equivalent to 1200 mg ibuprofen and 180 mg pseudoephedrine hydrochloride) must not be exceeded.
Treatment should not be continued for more than 5 days.
The lowest effective dose should be used for the shortest duration necessary to relieve symptoms (see section 4.4).
This combination product should be used where both, the decongestant action of pseudoephedrine hydrochloride and the analgesic and/or anti-inflammatory action of ibuprofen are required. If one symptom (either nasal congestion or headache and/or fever) predominates, single-agent therapy is preferable.
Paediatric population
Lasynac is contraindicated in paediatric patients below 15 years of age (see section 4.3).
If in adolescents this medicinal product is required for more than 3 days, or if symptoms worsen a physician should be consulted.
Method of administration
For oral use.
The film-coated tablets should be swallowed without chewing with a large glass of water, preferably during meals.
4.3 Contraindications
Known hypersensitivity to ibuprofen, pseudoephedrine hydrochloride or to any of the excipients listed in section 6.1;
Patients aged under 15 years;
Pregnancy and Lactation (see section 4.6);
History of allergy or asthma precipitated by ibuprofen or substances with similar activity such as other non-steroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid;
History of gastrointestinal bleeding or perforation related to previous antiinflammatory therapy;
Active peptic ulcer or history of recurrent ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding);
Cerebrovascular or other bleeding;
Unexplained haematopoietic abnormalities;
Severe hepatocellular insufficiency;
Severe renal failure;
Severe heart failure (NYHA Class IV);
Severe or poorly controlled hypertension;
History of stroke or presence of risk factors for stroke (because of the a-sympathomimetic activity of pseudoephedrine hydrochloride);
Severe coronary insufficiency;
Risk of closed-angle glaucoma;
Risk of urinary retention related to urethroprostatic disorders;
History of myocardial infarction;
History of seizures;
Disseminated lupus erythematosus;
Concomitant use of other vasoconstrictor agents used as nasal decongestants, whether administered orally or nasally (e.g. phenylpropanolamine, phenylephrine and ephedrine), and methylphenidate (see section 4.5);
Concomitant use of non-selective monoamine oxidase inhibitors (MAOIs) (iproniazid) (see section 4.5) or use of monoamine oxidase inhibitors within the last two weeks.
Patients with severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).
4.4 Special warnings and precautions for use
Concomitant use of Lasynac with other NSAIDs containing cyclo-oxygenase (COX)-2 inhibitors should be avoided.
Undesirable effects may be reduced by using the minimum effective dose for the shortest duration necessary to control symptoms (see „Gastro-intestinal effects“ and „Cardiovascular and cerebrovascular effects“ below).
Severe skin reactions
Severe skin reactions such as acute generalised exanthematous pustulosis (AGEP) may occur with ibuprofen and pseudoephedrine-containing products. This acute pustular eruption may occur within the first 2 days of treatment, with fever, and numerous, small, mostly non-follicular pustules arising on a widespread oedematous erythema and mainly localized on the skin folds, trunk, and upper extremities. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of Lasynac should be discontinued and appropriate measures taken if needed.
Special warnings related to pseudoephedrine hydrochloride:
The dosage, the recommended maximum duration of treatment (5 days) and the contraindications must be strictly adhered to (see section 4.8).
Patients should be informed that treatment must be discontinued if they develop hypertension, tachycardia, palpitations, cardiac arrhythmias, nausea or any neurological signs such as onset or worsening of headache.
Ischaemic colitis
Some cases of ischaemic colitis have been reported with pseudoephedrine. Pseudoephedrine should be discontinued and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis develop.
Ischaemic optic neuropathy
Cases of ischaemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or decreased visual acuity such as scotoma occurs.
Before using this product, patients should consult their physician in case of:
Hypertension, heart disease, hyperthyroidism, psychosis or diabetes.
Concomitant administration of antimigraine agents, especially ergot alkaloid vasoconstrictors (because of the a-sympathomimetic activity of pseudoephedrine).
SLE and mixed connective tissue disease: Systemic lupus erythematosus and mixed connective tissue disease – increased risk of aseptic meningitis (see section 4.8).
Neurological symptoms such as seizures, hallucinations, behavioural disturbances, agitation and insomnia. These have been described after systemic administration of vasoconstrictors, especially during febrile episodes or on overdose. These symptoms have been more commonly reported in paediatric population.
As a result, it is advisable:
to avoid administration of Lasynac either in combination with medicines which can lower the epileptogenic threshold, such as terpene derivatives, clobutinol, atropine-like substances and local anaesthetics, or where there is a history of seizures;
to adhere strictly to the recommended dosage in all cases and to inform the patients about the risks of overdose if Lasynac is taken concomitantly with other medicines containing vasoconstrictors.
Patients with urethroprostatic disorders are more prone to develop symptoms like dysuria and urinary retention.
Elderly patients may be more sensitive to the effects on the central nervous system (CNS).
Precautions for use related to pseudoephedrine hydrochloride:
In patients undergoing scheduled surgery in which volatile halogenated anaesthetics are to be used, it is preferable to discontinue treatment with Lasynac several days before surgery in view of the risk of acute hypertension (see section 4.5).Athletes should be informed that treatment with pseudoephedrine hydrochloride can lead to positive results in doping tests.
Interference with serological testing
Pseudoephedrine has the potential to reduce iobenguane i-131 uptake in neuroendocrine tumours, thus interfering with scintigraphy.
Special warnings related to ibuprofen:
Patients who have asthma associated with chronic rhinitis, chronic sinusitis and/or nasal polyposis have a higher risk of allergic reactions when taking acetylsalicylic acid and/or NSAIDs. These may present as Quincke’s oedema or urticaria. Administration of Lasynac may precipitate an acute asthma attack; particularly in some patients who are allergic to acetylsalicylic acid or an NSAID (see section 4.3).
Gastro-intestinal effects:
Gastro-intestinal bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of gastrointestinal events.
The risk of gastro-intestinal bleeding, ulceration or perforation, which can be fatal, is higher with increasing NSAID doses, in patients with a history of ulcer (particularly if complicated with bleeding or perforation (see section 4.3) and in patients older than 60 years of age. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking concomitant low-dose acetylsalicylic acid or other medicinal drug products likely to increase gastro-intestinal risk (see below and section 4.5).
Patients with a history of gastrointestinal toxicity, especially elderly patients, may present with unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment.
Particular caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding such as oral corticosteroids, anticoagulants such as warfarin, SSRIs or antiplatelet agents such as acetylsalicylic acid (see section 4.5).
Treatment with Lasynac should be discontinued immediately if gastrointestinal bleeding or ulceration occurs.
NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see section 4.8).
Cardiovascular and cerebrovascular effects:
Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low-dose ibuprofen (e.g. <1200 mg/daily) is associated with an increased risk of arterial thrombotic events.
Patients with uncontrolled hypertension, congestive heart failure (NYHA IIIII), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg/day) should be avoided.
Careful consideration should also be exercised before initiating longer-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of ibuprofen (2400 mg/day) are required.
Caution is required in patients with a history of hypertension and/or heart failure as fluid retention, hypertension or oedema have been observed in association with previous NSAID therapy; advice from a physician and/or pharmacist must be sought prior to starting treatment under these circumstances.
Skin reactions:
Serious skin reactions, some of them fatal, including bullous and exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients are at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Lasynac should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Masking of symptoms of underlying infections.
Lasynac can mask symptoms of infection, which may lead to delayed initiation of appropriate treatment and thereby worsening the outcome of the infection. This has been observed in bacterial community acquired pneumonia and bacterial complications to varicella. When Lasynac is administered for fever or pain relief in relation to infection, monitoring of infection is advised. In non-hospital settings, the patient should consult a doctor if symptoms persist or worsen.
It is advisable to avoid use of Lasynac in case of varicella.
Before using this product, patients should consult their physician in case of:
SLE and mixed connective tissue disease: Systemic lupus erythematosus and mixed connective tissue disease – increased risk of aseptic meningitis or hepatitis (see section 4.8).
congenital disorder of porphyrin metabolism (e.g. acute intermittent porphyria).
Severe acute hypersensitivity reactions (e.g. anaphylactic shock) are observed very rarely. At the first signs of hypersensitivity reaction after taking/administering Lasynac therapy must be stopped. Medically required measures, in line with the symptoms, must be initiated by specialist personnel.
Ibuprofen, the active substance of Lasynac may temporarily inhibit the bloodplatelet function (thrombocyte aggregation). Therefore, patients with platelet disorders should be monitored carefully.
In case of prolonged treatment with Ibuprofen, liver and kidney parameters as well as blood picture need to be checked regularly.
Prolonged use of any type of analgesics for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headache despite (or because of) the regular use of headache medications.
In general terms, the habitual intake of analgesics particularly on combination of several pain-relieving active substances, may lead to permanent renal damage with the risk of renal failure (analgesic nephropathy). This risk may be increased under physical strain associated with loss of salt and dehydration. Therefore, it should be avoided.
Through concomitant consumption of alcohol, active substance-related undesirable effects, particularly those that concern the gastrointestinal tract or the central nervous system, may be increased on use of NSAIDs.
Precautions for use related to ibuprofen:
Elderly: The pharmacokinetics of ibuprofen is not modified by age, no dose adjustments is necessary in the elderly. However, elderly patients should be carefully monitored as they are more sensitive to NSAID-related undesirable effects, particularly gastro-intestinal bleeding and perforation, which can be fatal.
Caution and special monitoring are required when administering ibuprofen to patients with a history of gastro-intestinal disease (such as peptic ulcer, hiatus hernia or gastrointestinal bleeding) and chronic inflammatory intestinal disease (ulcerative colitis, Crohn’s disease).
In the initial stages of treatment, careful monitoring of urine output and renal function is required in patients with heart failure, patients with chronically impaired renal or hepatic function, patients taking diuretics, patients who are hypovolaemic as a result of major surgery and, in particular, elderly patients.
There is a risk of renal impairment in dehydrated adolescents.
If visual disturbances occur during the course of treatment, a full ophthalmological examination should be carried out.
If symptoms persist or worsen, the patient should be advised to consult a physician.
Excipients with known effects:
Lasynac tablet contains lactose.
This product contains 84 mg lactose monohydrate per tablet (up to 504 mg per maximum recommended daily dose). Patients with rare hereditary conditions of galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Lasynac tablet contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
4.5 Interaction with other medicinal products and other forms of interaction
| Combination of pseudoephedrine with: | Possible Reaction |
| Non-selective MAOIs (iproniazid): | Paroxysmal hypertension and hyperthermia, which can be fatal. Because of the long duration of action of MAOIs, this interaction can occur up to 15 days after discontinuation of the MAOI. |
| Other indirectly-acting, orally or nasally administered sympathomimetics or vasoconstrictor agents, a-sympathomimetic drugs, phenylpropanolamine, phenylephrine, ephedrine, methylphenidate: | Risk of vasoconstriction and/or hypertensive crises. |
| Reversible inhibitors of monoamine oxidase A (RIMAs), linezolid, dopaminergic ergot alkaloids, vasoconstrictor ergot alkaloids: | Risk of vasoconstriction and/or hypertensive crises. |
| Volatile halogenated anaesthetics: | Perioperative acute hypertension. In scheduled surgery, discontinue treatment with Lasynac several days before. |
| Guanethidine, reserpine and methyldopa: | Effect of pseudoephedrine may be diminished. |
| Tricyclic antidepressants: | Effect of pseudoephedrine may be diminished or enhanced. |
| Digitalis, quinidine or tricyclic antidepressants: | Increased frequency of arrhythmia. |
| Beta-blockers: | Reduction of the antihypertensive effects of betablocker |
| Concomitant use of ibuprofen with: | Possible Reaction |
| Other NSAIDs, including salicylates: | The concomitant administration of several NSAIDs may increase the risk of gastrointestinal ulcers and bleeding due to a synergistic effect. The concomitant use of ibuprofen |
| with other NSAIDs should therefore be avoided (see section 4.4). | |
| Digoxin: | The concomitant use of Lasynac with digoxin preparations may increase serum levels of these medicinal products. A check of serum-digoxin is not as a rule required on correct use (maximum over 5 days). |
| Corticosteroids: | Corticosteroids as these may increase the risk of adverse reactions, especially of the gastrointestinal tract (gastrointestinal; ulceration or bleeding) (see section 4.3). |
| Anti-platel et agents: | Increased risk of gastrointestinal bleeding (see section 4.4). |
| Acetylsalicylic acid (low dose): | Concomitant administration of ibuprofen and acetylsalicylic acid is not generally recommended because of the potential of increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1). |
| Anticoagulants: (e.g.: warfarin, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, iloprost) | NSAIDs as ibuprofen may enhance the effect of anti-coagulants (see section 4.4). |
| Phenytoin: | The concomitant use of Lasynac |
| with phenytoin preparations may increase serum levels of these medicinal products. A check of serum-phenytoin levels is not as a rule required on correct use (maximum over 5 days). | |
| Selective serotonin reuptake inhibitors (SSRIs): | Increased risk of gastrointestinal bleeding (see section 4.4). |
| Lithium: | The concomitant use of Lasynac with lithium preparations may increase serum levels of these medicinal products. A check of serum-lithium is not as a rule required on correct use (maximum over 5 days). |
| Probenecid and sulfinpyrazone: | Medicinal products that contain probenecid or sulfinpyrazone may delay the excretion of ibuprofen. |
| Diuretics, ACE inhibitors, betareceptor-blockers and angiotensin-II antagonists: | NSAIDs may reduce the effect of diuretics and other antihypertensive medicinal products. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor, beta-receptor-blockers or angiotensin-II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter. |
| Potassium sparing diuretics: | The concomitant administration of Lasynac and potassium-sparing diuretics may lead to hyperkalaemia (check of serum potassium is recommended). |
| Methotrexate: | The administration of Lasynac within 24 hours before or after administration of methotrexate may lead to elevated concentrations of methotrexate and an increase in its toxic effect. |
| Ciclosporin: | The risk of a kidney-damaging effect due to ciclosporin is increased through the concomitant administration of certain nonsteroidal anti-inflammatory drugs. This effect also cannot be ruled out for a combination of ciclosporin with ibuprofen. |
| Tacrolimus: | The risk of nephrotoxicity is increased if the two medicinal products are administered concomitantly. |
| Zidovudine: | There is evidence of an increased risk of haemarthroses and haematoma in HIV (+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen. |
| Sulphonylureas: | Clinical investigations have shown interactions between nonsteroidal anti-inflammatory drugs and antidiabetics (sulphonylureas). Although interactions between ibuprofen and sulphonylureas have not been described to date, a check of blood-glucose values is recommended as a precaution on concomitant intake. |
| Quinolone antibiotics: | Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. |
| Heparins; Gingko biloba : | Increased risk of bleeding. |
| CYP2C9 inhibitors: | Concomitant administration of ibuprofen with CYP2C9 inhibitors may increase the exposure to |
| ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased S (+)-ibuprofen exposure by approximately 80 to 100% has been shown. Reduction of the ibuprofen dose should be considered when potent CYP2C9 inhibitors are administered concomitantly, particularly when high dose (2400 mg/day) ibuprofen is administered with either voriconazole or fluconazole. | |
| Mifepristone: | NSAIDs should not be used for 812 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone. |
4.6 Fertility, pregnancy and lactation
Pregnancy
Pseudoephedrine hydrochloride:
While no studies for reproductive toxicity, fertility and postnatal development with pseudoephedrine hydrochloride are available and pseudoephedrine hydrochloride has been in widespread use for many years without apparent ill consequence, an increased risk concerning the use of pseudoephedrine hydrochloride due to its vasoconstrictive effects in early pregnancy might exist.
Ibuprofen:
During the 3rd trimester, ibuprofen is contraindicated as there is a risk of premature closure of the foetal ductus arteriosus with possible persistent pulmonary hypertension. The onset of labour may be delayed and the duration increased with an increased bleeding tendency in both mother and child.
In conclusion, Lasynac is contraindicated during pregnancy and not recommended in women of childbearing potential not using contraception.
Breastfeeding
Pseudoephedrine hydrochloride passes into breast milk.
Ibuprofen and its metabolites are excreted into human breast milk in very low concentrations and are unlikely to have an adverse effect on breast-fed infants. In view of the potential cardiovascular and neurological effects of vasoconstrictor agents, the use of Lasynac is contraindicated during lactation.
Fertility
There is limited evidence that drugs which inhibit cyclo-oxygenase/prostaglandin synthesis may cause impairment of female fertility by an effect on ovulation. This is reversible upon withdrawal of treatment.
4.7 Effects on ability to drive and use machines
Lasynac has negligible influence on the ability to drive or use machines.
Patients should be warned about the potential occurrence of the ibuprofen related side effects dizziness or visual disturbances.
4.8 Undesirable effects
The most commonly-observed adverse events related to ibuprofen are gastrointestinal in nature. In general, the risk of development of adverse events (in particular the risk of development of serious gastrointestinal complications) increases with increasing dose and with increasing duration of treatment administration.
Hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of:
(a) Non-specific allergic reaction and anaphylaxis
(b) Respiratory tract reactivity comprising of asthma, aggravated asthma, bronchospasm or dyspnoea
© Assorted skin disorders, including rashes of various types, pruritis, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme)
In patients with existing auto-immune disorders (such as systemic lupus erythematosus, mixed connective tissue disease) during treatment with ibuprofen, single cases of symptoms of aseptic meningitis, such as stiff neck, headache, nausea, vomiting, fever or disorientation have been observed.
Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment.
Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).
The following list of adverse effects relates to those experienced with ibuprofen and pseudoephedrine hydrochloride at OTC doses, for short-term use. In the treatment of chronic conditions, under long-term treatment, additional adverse effects may occur.
Patients should be informed that they should stop taking Lasynac 200mg/30mg film coated tablets immediately and consult a physician if they experience a serious adverse drug reaction.
<Very common (>1/10)>__________
<Common (>1/100 to <1/10)>______
<Uncommon (>1/1,000 to <1/100)>
<Rare (>1/10,000 to <1/1,000)>
<Very rare (<1/10,000)>____________
<not known (cannot be estimated from the available data)>____________
Tabulated summary of adverse
reactions
| Infections and infestations | Ibuprofen | Very rare | Exacerbation of infectious inflammations (e.g. necrotizing fasciitis), Aseptic meningitis (stiffness of the neck, headache, nausea, vomiting, fever or disorientation in patients with preexistent autoimmune diseases (SLE, mixed connective tissue disease) |
| Blood and lymphatic system disorders | Ibuprofen | Very rare | Haematopoietic disorders (anaemia, leukopenia, thrombocytopeni a, pancytopenia, agranulocytosis) |
| Immune system disorders | Ibuprofen | Uncommo n | Hypersensitivity reactions with urticaria, pruritus and asthma attacks (with drop in blood pressure) |
| Ibuprofen and pseudoephedrine hydrochloride | Very rare | Severe generalised hypersensitivity reactions, signs may be facial oedema, angioedema, dyspnoea, tachycardia, drop in blood pressure, |
| anaphylactic shock | |||
| Psychiatric disorders | Ibuprofen | Very rare | Psychotic reactions, depression |
| Pseudoephedrine hydrochloride | Not known | Agitation, hallucination, anxiety, abnormal behavior, insomnia | |
| Nervous system disorders | Ibuprofen | Uncommo n | Central nervous disturbances such as headache, dizziness, sleeplessness, agitation, irritability or tiredness |
| Pseudoephedrine hydrochloride | Not known | Haemorrhagic stroke, ischemic stroke, convulsion, headache | |
| Eye disorders | Ibuprofen | Uncommo n | Visual disturbances |
| Pseudoephedrine hydrochloride | Not known | Ischemic optic neuropathy | |
| Ear and labyrinth disorders | Ibuprofen | Rare | Tinnitus |
| Cardiac disorders | Ibuprofen | Very rare | Palpitations, heart failure, myocardial infarction |
| Pseudoephedrine hydrochloride | Not known | Palpitations, tachycardia, chest pain, arrythmia | |
| Vascular disorders | Ibuprofen | Very rare | Arterial hypertension, vasculitis |
| Pseudoephedrine hydrochloride | Not known | Hypertension | |
| Gastrointestinal disorders | Ibuprofen | Common | Dyspepsia, pyrosis, abdominal pain, nausea, vomiting, flatulence, diarrhoea, constipation, minor gastrointestinal blood loss in rare cases leading to anaemia |
| Ibuprofen | Uncommo n | Gastric ulcer with bleeding and/or |
| perforation, gastritis, ulcerous stomatitis, exacerbation of colitis and Crohn’s disease (see section 4.4) | |||
| Ibuprofen | Very rare | Oesophagitis, pancreatitis, intestinal diaphragm-like stricture | |
| Pseudoephedrine hydrochloride | Not known | Dry mouth, thirst, nausea, vomiting, ischaemic colitis | |
| Hepatobiliary disorders | Ibuprofen | Very rare | Hepatic dysfunction, hepatic damage, particularly in longterm therapy, hepatic failure, acute hepatitis |
| Skin and subcutaneous tissue disorders | Ibuprofen | Uncommo n | Various skin rashes |
| Ibuprofen | Very rare | Bullous exanthema such as Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), alopecia, severe skin infections, soft-tissue complications in a varicella infection | |
| Ibuprofen | Not known | Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), photosensitivity reaction, Acute generalised exanthematous pustulosis (AGEP) | |
| Pseudoephedrine hydrochloride | Not known | Severe skin reactions, including acute generalized exanthematous pustulosis (AGEP), rash, urticaria, pruritus, hyperhidrosis |
| Renal and Urinary disorders | Ibuprofen | Rare | Kidney-tissue damage (papillary necrosis) and elevated uric acid concentrations in the blood |
| Ibuprofen | Very rare | Oedemas (particularly in patients with arterial hypertension or renal insufficiency), nephrotic syndrome, interstitial nephritis, acute renal insufficiency | |
| Pseudoephedrine hydrochloride | Not known | Difficulty in micturition |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.1 Pharmacodynamic propertiesPharmacotherapeutic group: Other cold combination preparations. ATC codes: R05X
Mechanism of action
Pseudoephedrine hydrochloride is a sympathomimetic agent which, when administered systemically, acts as a nasal decongestant.
Ibuprofen is an NSAID belonging to the propionic acid class of drugs. It is an arylcarboxylic acid derivative which has analgesic, antipyretic and antiinflammatory properties as well as a short-acting inhibitory effect on platelet function. All of these properties are related to its ability to inhibit prostaglandin synthesis.
Lasynac is a combination of a vasoconstrictor (pseudoephedrine hydrochloride) with an analgesic, antipyretic and anti-inflammatory dose of an NSAID (ibuprofen).
Pharmacodynamic effects
Clinical efficacy and safety
Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Some pharmacodynamic studies show that when single doses of ibuprofen 400mg were taken within 8 h before or within 30 min after immediate release acetilsalicylic acid dosing (81mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. Although there are uncertainties regarding extrapolation of these data to the clinical situation , the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 4.5).
5.2 Pharmacokinetic properties
Ibuprofen:
Absorption:
Peak plasma levels following oral administration are achieved within 90 min. Following a single dose, peak plasma levels in healthy adults are proportional to the dose administered (Cmax is 17 ± 3.5 |ig/ml for a dose of 200 mg and 30.3 ± 4.7 |ig/ml for a dose of 400 mg). Absorption of ibuprofen is delayed by food.
Distribution:
Ibuprofen is not associated with any accumulation phenomena. Plasma protein binding is 99%.
In synovial fluid, stable levels of ibuprofen are found between 2 and 8 h after administration; the synovial fluid Cmax is about one-third the Cmax in plasma. The quantity of ibuprofen detected in the milk of breastfeeding women is less than 1 mg/24 h following administration of 400 mg every 6 h.
Biotransformation:
Ibuprofen is not an enzyme inducer. About 90% of a dose is metabolised to inactive metabolites.
Elimination:
Ibuprofen is principally eliminated in the urine, with 10% being in unchanged form and 90% in the form of inactive metabolites, which are mainly formed by glucuronide conjugation. Elimination is complete within 24 h.
The elimination half-life is about 2 h.
Age, renal impairment and hepatic impairment do not affect the pharmacokinetic parameters to any major extent and the variations observed are not sufficient to warrant any dosage adjustments.
Linearity/non-linearity:
The pharmacokinetics of ibuprofen is linear at therapeutic doses.
Pseudoephedrine hydrochloride:
Elimination:
Following oral administration, pseudoephedrine hydrochloride is largely excreted unchanged (70 – 90%) in the urine.
The elimination half-life depends on urinary pH. Urinary alkalinisation leads to an increase in tubular reabsorption and thus to an increase in the elimination half-life.
5.3 Preclinical safety data
Ibuprofen:
Absorption:
Peak plasma levels following oral administration are achieved within 90 min. Following a single dose, peak plasma levels in healthy adults are proportional to the dose administered (Cmax is 17 ± 3.5 |ig/ml for a dose of 200 mg and 30.3 ± 4.7 |ig/ml for a dose of 400 mg). Absorption of ibuprofen is delayed by food.
Distribution:
Ibuprofen is not associated with any accumulation phenomena. Plasma protein binding is 99%.
In synovial fluid, stable levels of ibuprofen are found between 2 and 8 h after administration; the synovial fluid Cmax is about one-third the Cmax in plasma. The quantity of ibuprofen detected in the milk of breastfeeding women is less than 1 mg/24 h following administration of 400 mg every 6 h.
Biotransformation:
Ibuprofen is not an enzyme inducer. About 90% of a dose is metabolised to inactive metabolites.
Elimination:
Ibuprofen is principally eliminated in the urine, with 10% being in unchanged form and 90% in the form of inactive metabolites, which are mainly formed by glucuronide conjugation. Elimination is complete within 24 h.
The elimination half-life is about 2 h.
Age, renal impairment and hepatic impairment do not affect the pharmacokinetic parameters to any major extent and the variations observed are not sufficient to warrant any dosage adjustments.
Linearity/non-linearity:
The pharmacokinetics of ibuprofen is linear at therapeutic doses.
Pseudoephedrine hydrochloride:
Elimination:
Following oral administration, pseudoephedrine hydrochloride is largely excreted unchanged (70 – 90%) in the urine.
The elimination half-life depends on urinary pH. Urinary alkalinisation leads to an increase in tubular reabsorption and thus to an increase in the elimination half-life.
6.1 List of excipients
Ibuprofen:
Absorption:
Peak plasma levels following oral administration are achieved within 90 min. Following a single dose, peak plasma levels in healthy adults are proportional to the dose administered (Cmax is 17 ± 3.5 |ig/ml for a dose of 200 mg and 30.3 ± 4.7 |ig/ml for a dose of 400 mg). Absorption of ibuprofen is delayed by food.
Distribution:
Ibuprofen is not associated with any accumulation phenomena. Plasma protein binding is 99%.
In synovial fluid, stable levels of ibuprofen are found between 2 and 8 h after administration; the synovial fluid Cmax is about one-third the Cmax in plasma. The quantity of ibuprofen detected in the milk of breastfeeding women is less than 1 mg/24 h following administration of 400 mg every 6 h.
Biotransformation:
Ibuprofen is not an enzyme inducer. About 90% of a dose is metabolised to inactive metabolites.
Elimination:
Ibuprofen is principally eliminated in the urine, with 10% being in unchanged form and 90% in the form of inactive metabolites, which are mainly formed by glucuronide conjugation. Elimination is complete within 24 h.
The elimination half-life is about 2 h.
Age, renal impairment and hepatic impairment do not affect the pharmacokinetic parameters to any major extent and the variations observed are not sufficient to warrant any dosage adjustments.
Linearity/non-linearity:
The pharmacokinetics of ibuprofen is linear at therapeutic doses.
Pseudoephedrine hydrochloride:
Elimination:
Following oral administration, pseudoephedrine hydrochloride is largely excreted unchanged (70 – 90%) in the urine.
The elimination half-life depends on urinary pH. Urinary alkalinisation leads to an increase in tubular reabsorption and thus to an increase in the elimination half-life.
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years
6.4 Special precautions for storage
Do not store above 25°C.
Store in the original package. Keep blister in the outer carton.
6.5 Nature and contents of container
PVC/PVDC/aluminium foil blister.
Pack sizes: 10, 20.
Not all pack sizes may be marketed.